ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 38710951

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Rodón J and 14 others. Nat Med, 2024. Cited by 64 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Papers, record 38710951. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38710951

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
PubMed
Journal
Nat Med
PubMed
Year
2024
PubMed
Publication types
Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
64
iCite
Relative citation ratio, by iCite
7.41, provisional
iCite
Revised in PubMed
2026-06-18
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rodón JJordihttps://orcid.org/0000-0001-6467-3632
2Damian SSilviahttps://orcid.org/0000-0001-9560-1092
3Furqan MMuhammad
4García-Donas JJesúshttps://orcid.org/0000-0001-7731-3601
5Imai HHiroo
6Italiano AAntoinehttps://orcid.org/0000-0002-8540-5351
7Spanggaard IIbenhttps://orcid.org/0000-0001-5925-2630
8Ueno MMakoto
9Yokota TTomoyahttps://orcid.org/0000-0001-7327-7949
10Veronese MLMaria Luisa

1 to 10 of 15Source PubMed

See all 15 authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptor, Fibroblast Growth Factor, Type 3Major topic
Receptor, Fibroblast Growth Factor, Type 1Major topic
PyrimidinesMajor topic
NeoplasmsMajor topic
Humans
Female
Male
Middle Aged
Adult
Aged
Mutation
Protein Kinase Inhibitors
Progression-Free Survival
Drug Resistance, Neoplasm
Morpholines
Pyrroles

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA086862NCI NIH HHSUnited StatesP30CA086862PubMed and NIH

Source NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03822117
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Derived from the trialYes

Source ClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in38,789,647Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.https://conductscience.org/library/papers/38789647

Source PubMed

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128,303,906Advances and challenges in targeting FGFR signalling in cancer.Nat Rev Cancer2017https://conductscience.org/library/papers/28303906PubMed
236,462,464Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.ESMO Open2022https://conductscience.org/library/papers/36462464PubMed
326,373,574The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Clin Cancer Res2016https://conductscience.org/library/papers/26373574PubMed
432,879,300FGF/FGFR signaling in health and disease.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32879300PubMed
537,541,273Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.Lancet Oncol2023https://conductscience.org/library/papers/37541273PubMed
635,176,457FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.Ann Oncol2022https://conductscience.org/library/papers/35176457PubMed
734,551,969Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.Cancer Discov2022https://conductscience.org/library/papers/34551969PubMed
827,870,574
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
J Clin Oncol2017https://conductscience.org/library/papers/27870574PubMed
932,315,352INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.PLoS One2020https://conductscience.org/library/papers/32315352PubMed
1028,416,604Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.Mol Cancer Ther2017https://conductscience.org/library/papers/28416604PubMed

1 to 10 of 34

See all 34 references

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.

PMIDTitleJournalYearIn PapersSource
42,881,857
Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
J Clin Med2026https://conductscience.org/library/papers/42881857PubMed
42,618,642Exploring the landscape of targetable alterations in patients with glioblastoma.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42618642PubMed
42,498,744Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).Br J Cancer2026https://conductscience.org/library/papers/42498744PubMed
42,286,159Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.NPJ Precis Oncol2026https://conductscience.org/library/papers/42286159PubMed
42,223,137Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.J Clin Oncol2026https://conductscience.org/library/papers/42223137PubMed
42,192,928Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?Cancers (Basel)2026https://conductscience.org/library/papers/42192928PubMed
42,058,998FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors.Neurooncol Adv2026https://conductscience.org/library/papers/42058998PubMed
41,874,881Recent Advances in Targeted Therapies for Adult Gliomas.Curr Neurol Neurosci Rep2026https://conductscience.org/library/papers/41874881PubMed
41,849,383The conserved fibroblast growth factor receptor-based signaling is required for dendrite regeneration.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41849383PubMed
41,832,306FGF family in health and disease.Mol Biomed2026https://conductscience.org/library/papers/41832306PubMed

1 to 10 of 45

See all 45 cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BAP18,314PubTator's text mininghttps://conductscience.org/library/genes/8314NCBI Gene
FGFR12,260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
FGFR32,261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene
TP537,157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PEMIGATINIBCHEMBL4297522Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4297522

Source ChEMBL

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
dbGaPphs003590.v1.p1

Source PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38710951

GET https://conductscience.org/api/papers/v1/38710951/references?page=2

API referenceFor AI assistants